CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery
Open Access
- 22 October 2018
- journal article
- research article
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 32 (6) , 1533-1540
Abstract
Background/Aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of digestive cancer. Recurrence within one year after surgery is inevitable in most PDAC patients. Recently, cluster of differentiation 44 (CD44) has been shown to be associated with tumor initiation, metastasis and prognosis. This study aimed to explore the correlation of CD44 expression with clinicopathological factors and the role of CD44 in predicting early recurrence (ER) in PDAC patients after radical surgery. Materials and Methods: PDAC patients who underwent radical resection between January 1999 and March 2015 were enrolled in this study. Tumor recurrence within 6 months after surgery was defined as ER. Immunohistochemical staining was performed with anti-CD44 antibodies. The association between clinicopathological parameters and CD44 expression was analyzed. Predictors for ER were also assessed with univariate and multivariate analyses. Results: Overall, 155 patients were included in this study. Univariate analysis revealed CA19-9 levels (p=0.014), CD44 histoscores (H-scores; p=0.002), differentiation (p=0.010), nodal status (p=0.005), stage (p=0.003), vascular invasion (p=0.007), lymphatic invasion (p<0.001) and perineural invasion (p=0.042) as risk factors for ER. In multivariate analysis, high CA19-9 levels and CD44 H-scores and poor differentiation independently predicted ER. Conclusion: High CA19-9 levels, CD44 H-scores and poor differentiation are independent predictors for ER in PDAC patients undergoing radical resection. Therefore, the determination of CD44 expression might help in identifying patients at a high risk of ER for more aggressive treatment after radical surgery.Keywords
This publication has 41 references indexed in Scilit:
- Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical centerAsian Journal of Surgery, 2018
- Prognosis of ductal adenocarcinoma of pancreatic head with overexpression of CD44Formosan Journal of Surgery, 2014
- Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?Surgery, 2012
- Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancerCancer, 2009
- CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinomaJournal of Hepato-Biliary-Pancreatic Surgery, 2007
- CA 19-9 Levels Predict Results of Staging Laparoscopy in Pancreatic CancerJournal of Gastrointestinal Surgery, 2005
- Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicatorsJournal of Gastrointestinal Surgery, 2000
- Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesisin vitroInternational Journal of Cancer, 1996
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990